News – Nang Kuang Medicine Trading Limited

Press release for Eklira entering China NRDL_AZ 06.23.2026

PP-EKL-7577-CHI-EN-v1 Nang Kuang Medicine Trading Limited and Azurity Pharmaceuticals Announce that Aclidinium Bromide Powder for Inhalation (marketed under the trademark Eklira® Genuair®) is Now Included in China’s National Reimbursement Drug List for Chronic Obstructive Pulmonary Disease Treatment [HongKong 7th December] — Nang Kuang Medicine Trading Limited and Azurity Pharmaceuticals announced that aclidinium bromide powder for … Continue reading

Nang Kuang Partners with Frenius Kabi to Exclusively Commercialize Vitamin D3 Drops in Mainland China

In 2020 Nang Kuang and Frenius Kabi entered into an exclusive agreement for commercializing Oleovit® Oral Vitamin D3 Drops for the treatment of Vitamin D deficiency in infants, children and adults. Frenius Kabi is among TOP500 pharmaceutical companies in the world… Continue reading

Nang Kuang Obtains Global MAH Rights of Inhalation Formulation

Nang Kuang and Austrian pharmaceutical company Cyathus Exquirere entered into an exclusive agreement for MAH rights of an inhalation product in 2019. Cyathus Exquirere is a pharmaceutical company incorporated in the year 2000 in Vienna, Austria… Continue reading

Nang Kuang and Molteni Enter into an Exclusive Agreement to Commercialize Pain Management Product in Chinese Mainland

Nang Kuang and Molteni Farmaceutici (Molteni) have signed an exclusive agreement in August 2020 for the commercialization of pain management therapy in Mainland China for post-operative care of cancer patients. Molteni is a leading pharmaceutical company in Europe founded in 1892. It is a specialty leader in the opioid drug market researching and developing solutions … Continue reading

Nang Kuang and Zentrale Enter into an Exclusive Agreement to Commercialize Biological Product in Chinese MainlandNang Kuang and Zentrale Enter into an Exclusive Agreement

Nang Kuang and Pharma-Zentrale GmbH (Zentrale) have signed an exclusive agreement for the commercialization of an orally administered biological product in Mainland China for the treatment of diarrhea in infants, children and adults. Zentrale is a German century-old company specialized in probiotic- and phyto-pharmaceuticals, biological APIs as well as contract manufacturing… Continue reading

Nang Kuang Partners with Ferrer to Exclusively Distribute ERTACZO® in Mainland China and Hong Kong SAR

BEIJING Apr. 30, 2024—- Nang Kuang and the Spanish pharmaceutical company Ferrer Internacional, S.A. (Ferrer) have signed an agreement for the exclusive distribution of ERTACZO® (sertaconazole nitrate cream) in Mainland China and Hong Kong SAR. Sertaconazole nitrate is a new broad-spectrum imidazole antifungal agent. ERTACZO® is indicated for the topical treatment of interdigital tinea pedis … Continue reading